VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
August 09 2021 - 4:05PM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression, and other central nervous system (“CNS”)
disorders, today announced that it will host a conference call
on Thursday, August 12 at 2:00 pm Pacific
Time (5:00 pm Eastern Time) to discuss its financial and
operating results for its fiscal year 2022 first quarter ended June
30, 2021 and provide a business update.
Event: VistaGen Therapeutics Fiscal Year
2022 First Quarter Financial Results Conference
CallDate: Thursday, August 12,
2021Time: 2:00 pm Pacific Time (5:00 pm
Eastern Time)US Dial-in (Toll
Free): 1-800-935-5014Toll/International
Dial-in: 1-212-231-2920Conference
ID: 21996610
Shawn Singh, CEO of VistaGen, will host the conference call
along with other members of the Company’s management team. The call
is open to the public and will provide an update on recent
developments, milestones during the first quarter of the Company’s
2022 fiscal year, which ended June 30, 2021, and certain target
milestones and goals for future periods.
A live audio webcast of the conference call will be available
via this link –
http://public.viavid.com/index.php?id=146257.
Participants should access this webcast site 10 minutes
before the start of the call. In addition, a telephone playback of
the call will be available after approximately 5:00 pm Pacific
Time on Thursday, August 12, 2021. To listen to the
replay, call toll free 1-844-512-2921 within the United
States or 1-412-317-6671 when calling internationally (toll
applies). Please use the replay PIN 21996610.
About VistaGenVistaGen Therapeutics is a
biopharmaceutical company committed to developing and
commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three CNS drug candidates
has a differentiated profile and therapeutic potential in multiple
CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on Twitter,
LinkedIn, and Facebook.
VistaGen Company ContactsMedia:Mark
McPartlandPhone: (650) 577-3606Email: IR@vistagen.com
Investors:Mark FlatherPhone: (650) 577-3617Email:
IR@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Sep 2023 to Sep 2024